Head and neck cancers are diverse and increasing in prevalence. Treatment usually consists of a combination of surgery, radiotherapy and chemotherapy. However, the results of treatment can have significant lasting effects. Implementation of new surgical techniques (eg. da Vinci Robotic Surgical System), improved radiotherapy and advanced high-resolution fusion imaging aim to reduce these effects. In addition, the Centre is actively engaged in a variety of novel cutting-edge scientific clinical trials that aim to deliver new therapies to improve patient outcomes.

  • Director:
    •  Professor Ben Panizza, Director, Otolaryngology – Head and Neck Surgery, Princess Alexandra Hospital
  • Research
    Da Vinci Robot-5

    • Phase I dose-escalation study to determine the safety and tolerability of an intra-tumoural injection of EBC-46 in patients with refractory cutaneous or subcutaneous tumours.
    • Open-label Phase I study investigating the safety and efficacy of Cetuximab and prochlorperazine (STEMetil) combination therapy in patients with metastatic Head and Neck Squamous Cell Carcinoma and Triple Negative Breast Cancer (CESTEM study).
    • Phase I/II open-label clinical trial of autologous Epstein-Barr virus-specific T cell therapy as consolidative treatment following chemotherapy for metastatic EBV-associated nasopharyngeal carcinoma.
    • Primary trans-oral surgical management of early tonsillar squamous cell carcinoma followed by risk-adapted radiotherapy.
    • A blind randomised multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic radiosensitizer nimorazole (Nimoral), using a 15 gene signature for hypoxia in the treatment of HPV/p16 negative squamous cell carcinoma of the head and neck.
      • Danish Head and Neck Cancer Group (DAHANCA)/EORTC.
    • Chemotherapy de-escalation study for cancer patients with Human Papilloma Virus – and anti – epidermal growth factor receptor (cetuximab).
      • The Trans Tasman Radiation Oncology Group (TROG).
    • Drop Neck Study; neck dissection in cutaneous metastatic disease to the parotid.
  • Collaborations
    • The Trans Tasman Radiation Oncology Group (TROG)
    • UQ Diamantina Institute
    • QIMR Berghofer Medical Research Institute
    • Gold Coast University Hospital
    • University of Hong Kong
    • Translational Research Institute
    • Danish Head and Neck Cancer Group (DAHANCA)/EORTC
  • Key Personnel
    • Prof Ben Panizza
    • Prof Sandro Porceddu
    • Dr Chris Perry
    • Dr Fiona Simpson
    • Prof Rajiv Khanna.